# EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07410676/  
OnCo record `nct07410676` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pembrolizumab in pancreatic cancer, run by Essen Biotech, now recruiting.

## Summary

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07410676 by Essen Biotech, with a registry enrolment figure of 83 participants, started 2026-02-01 and due to reach its primary completion in 2028-12-21. Interventions recorded: EBNK-001 + IL-15 + Pembrolizumab. Conditions listed: Cancer; Sarcoma; Leukaemia; Breast Cancer (Locally Advanced or Metastatic); Lung Cancer (Diagnosis); Colorectal Cancer; Melanoma (Skin Cancer); Bladder Cancer; Kidney Cancer; Pancreatic Cancer Metastatic; Liver Cancer (Primary and Metastatic); Ovarian Cancer; Esophageal Cancer; Glioblastoma; Non-Melanoma Skin Cancer. Primary outcome: Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Incidence of Dose-Limiting Toxicities (DLTs). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: EBNK-ST-001
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07410676
- Phase: 1/2
- Setting: An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors
- Sponsor: Essen Biotech
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT07410676: https://clinicaltrials.gov/study/NCT07410676

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07410676.json